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A subcutaneous adipose tissue–liver signalling axis
controls hepatic gluconeogenesis
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The search for effective treatments for obesity and its comorbidities is of prime importance.
We previously identified IKK-e and TBK1 as promising therapeutic targets for the treatment of
obesity and associated insulin resistance. Here we show that acute inhibition of IKK-e and
TBK1 with amlexanox treatment increases cAMP levels in subcutaneous adipose depots of
obese mice, promoting the synthesis and secretion of the cytokine IL-6 from adipocytes and
preadipocytes, but not from macrophages. IL-6, in turn, stimulates the phosphorylation of
hepatic Stat3 to suppress expression of genes involved in gluconeogenesis, in the process
improving glucose handling in obese mice. Preliminary data in a small cohort of obese
patients show a similar association. These data support an important role for a subcutaneous
adipose tissue–liver axis in mediating the acute metabolic benefits of amlexanox on glucose
metabolism, and point to a new therapeutic pathway for type 2 diabetes.
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A
ccumulating evidence indicates that the chronic low-grade
inflammation associated with obesity plays an important
role in the development of metabolic disease. Obesity
induces an increase in the NF-kB pathway1–3, which leads to
induction of the non-canonical IKKs, IKK-e and TBK1 in adipose
tissue and liver4–7. Once induced, these kinases can initiate
a counter-inflammatory programme by phosphorylating and
activating phosphodiesterase 3B (PDE-3B) in adipocytes, thus
producing reduced levels of cAMP and resistance to stimulation
by catecholamines such as epinephrine and norepinephrine8. This
resulting catecholamine resistance reduces energy expenditure
and thermogenesis, and contributes to the development of obesity
in humans and mice8–12. Our previous studies demonstrated that
inhibition of IKK-e/TBK1 with the dual-specificity inhibitor
amlexanox improved catecholamine and insulin resistance, and
resulted in significant weight loss and reversal of metabolic
disease in obese mice, but had no effect on normal-chow fed mice
in which the kinases are not elevated8,13.
While improved catecholamine sensitivity may account for the
dramatic weight loss observed after IKK-e and TBK1 inhibition
in obese mice, the mechanism of improved insulin sensitivity
and glucose handling remains uncertain. A euglycemic–
hyperinsulinemic clamp revealed that the insulin-sensitizing
effects of amlexanox were mainly attributed to suppression of
hepatic glucose production13. Moreover, insulin sensitization was
observed prior to significant weight loss in obese mice. However,
it was not clear whether the effects of amlexanox in the liver were
mediated through direct inhibition of hepatic IKK-e/TBK1 or
another indirect mechanism. Here we describe one indirect
pathway by which inhibition of IKK-e and TBK1 in the
subcutaneous adipose tissue affects reduced hepatic glucose
production. Specifically, inhibition of IKK-e and TBK1 by
amlexanox stimulates the secretion of interleukin-6 (IL-6) from
adipocytes as well as preadipocytes in the subcutaneous adipose
tissue via a cAMP/p38-dependent pathway. The resulting increase
in serum IL-6 is responsible for the activation of hepatic Stat3,
which suppresses expression of G6pc to reduce hepatic glucose
output.
Results
Direct versus indirect effects of amlexanox in the liver. To
determine the mechanism by which amlexanox improves hepatic
insulin sensitivity, we performed RNA sequencing analysis of
hepatic gene expression a few hours after in vivo amlexanox
treatment, and identified over 1,700 differentially expressed genes
(GEO accession code GSE57054). Pathway analysis of these
differentially regulated genes revealed that the top two most
enriched pathways were the adipocytokine signalling pathway
and the Jak/Stat signalling pathway, presumably activated by a
tissue-derived ligand (Supplementary Table 1).
Amlexanox treatment induces IL-6 signalling. The pre-
ponderance of Jak/Stat responsive genes in the RNA sequencing
analysis led us to hypothesize that early effects of amlexanox in
the liver might, at least partially, be due to the increased
appearance of cytokines in the circulation. We thus screened
serum from amlexanox-treated obese mice for a series of
cytokines known to be upstream of the Jak/Stat pathway, and
identified one, IL-6. Time course studies revealed that serum IL-6
levels were significantly elevated soon after amlexanox treatment,
peaking 4 h after gavage with the drug (Fig. 1a,b). Increased
serum levels of leukemia-inducible factor were also observed with
amlexanox treatment; this IL-6 family ligand may also contribute
to the effects of amlexanox on Jak/Stat signalling (Supplementary
Fig. 1). No changes in other IL-6 family ligands, including leptin,
were observed. To identify the source of IL-6, we performed gene
expression analysis in various tissues from mice treated for 4 h
with amlexanox. No difference was observed in muscle, liver or
epididymal fat Il6 messenger RNA (mRNA) levels (Fig. 1c).
However, there was a significant increase in Il6 expression in the
inguinal adipose tissue. Consistent with preferential induction of
Il6 expression in subcutaneous fat, we also observed increased
expression in the dorsal subcutaneous depot, but not in the
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Figure 1 | Inhibition of IKK-e/TBK1 by amlexanox results in IL-6 secretion
from subcutaneous adipose tissue. (a) Time course of IL-6 secretion after
amlexanox administration (n¼4 mice per time point). (b) Serum IL-6 levels
4 h after amlexanox treatment (n¼8 mice per treatment). (c) Il6 gene
expression across tissues. BAT, brown adipose tissue (n¼ 8 mice per
treatment); WAT, white adipose tissue. (d) Relative Il6 expression in
different fat pads (n¼8 mice per treatment). * indicates a P valueo0.05
(heteroscedastic t-test (a,b), students t-test (c,d)) amlexanox versus
vehicle. Error bars presented as s.e.m.
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perirenal visceral fat (Fig. 1d). The precise mechanism regulating
the depot specificity of Il6 expression is unclear, as similar dif-
ferences are not observed when the tissues are treated ex vivo8.
Amlexanox induces Il6 expression specifically in adipocytes. To
determine which cell type within the subcutaneous fat was
responsible for amlexanox-stimulated IL-6 secretion, we fractio-
nated the tissue and measured Il6 expression levels in the various
cell types. Increased Il6 expression was observed both in mature
adipocytes and the stromal vascular cells (SVC) (Fig. 2a). Emr1
expression was restricted to the SVC, indicating that there was
negligible macrophage contamination of the mature adipocyte
fraction from the inguinal white adipose tissue (Fig. 2b).
As expected, Adipoq expression was exclusive to the mature
adipocytes (Fig. 2c). We further sorted the SVC to evaluate the
amlexanox-induced Il6 expression in preadipocytes versus
immune cells (Fig. 2d,e). Emr1 expression was exclusive to the
CD45þ cells, confirming the sorting of macrophages into this
population (Fig. 2f). In addition, enriched expression of Pdgfra
confirmed the identity of the preadipocyte population (Fig. 2g).
Amlexanox induced Il6 expression specifically in the preadipocyte
population but not in CD45þ cells (Fig. 2h). Importantly other
cytokines such as Tnfa were specifically expressed in the CD45þ
immune cells (Fig. 2i). These data indicate that amlexanox
specifically directs Il6 expression in adipocytes as well as
preadipocytes, but interestingly not in immune cells such as
macrophages.
Induction of Il6 expression in adipocytes via cAMP signalling.
In adipocytes, IKK-e and TBK1 phosphorylate and activate
PDE-3B, thereby reducing intracellular cAMP levels and
contributing to catecholamine resistance8, which has been
well-described in obese rodents and patients9,10,12. Inhibition of
IKK-e/TBK1 by amlexanox in vivo and in vitro relieves this
inhibition and restores catecholamine sensitivity8. Downstream
of cAMP, p38 activation leads to increased expression of Ucp1
(refs 14–16), which likely contributes to increased energy
expenditure in amlexanox-treated mice. Interestingly, the Il6
gene is also reported to be a downstream target of cAMP
signalling17,18. Consistently, treatment of 3T3-L1 adipocytes with
the b-adrenergic agonists isoproterenol and CL316,243, as well as
the adenylyl cyclase activator, forskolin, significantly increased Il6
expression (Fig. 3a).
To recapitulate the obese state, we overexpressed wild-type
IKK-e in 3T3-L1 adipocytes, which was sufficient to cause
catecholamine resistance and block the upregulation of Il6 in
response to CL316,243 (Fig. 3b). Importantly, the kinase dead
mutant of IKK-e was without effect. Furthermore, consistent with
an inhibitory effect of IKK-e and TBK1 on cAMP signalling,
pretreatment of cells with amlexanox significantly potentiated the
effect of CL316,243 on Il6 expression (Fig. 3c). Amlexanox also
increased Il6 expression in undifferentiated 3T3-L1 fibroblasts
(Fig. 3d), but failed to induce Il6 expression in the RAW264.7
macrophage cell line (Fig. 3e,f), consistent with the expression
pattern described above for SVC in vivo. As a positive control, we
further investigated Il6 expression in RAW264.7 macrophages. As
expected RAW264.7 cells robustly produce IL-6 in response to
lipopolysaccharide, via the NF-kB pathway (Fig. 3g,h). However,
unlike adipocytes, RAW264.7 macrophages do not produce IL-6
in response to forskolin, indicating that IL-6 production in
macrophages occurs through a pathway different from that used
in adipocytes (Fig. 3i,j).
Amlexanox-induced IL-6 expression is cAMP/p38 dependent.
Treatment of 3T3-L1 adipocytes with amlexanox alone for 2 h
significantly increased Il6 expression (Fig. 4a). The amlexanox-
induced increase in Il6 expression correlated with secretion of
IL-6 from 3T3-L1 adipocytes into the cell culture media 4 h after
treatment (Fig. 4b). As predicted by the proposed mechanism
involving reduced PDE-3B activity, amlexanox induced a sig-
nificant increase in cellular cAMP levels in adipocytes (Fig. 4c),
confirming that the drug increases IL-6 secretion from adipocytes
via increased cAMP signalling.
Induction of Il6 by cAMP has been previously shown to be
dependent on p38 (refs 18–20). Consistent with this notion, p38
phosphorylation increased after amlexanox treatment (Fig. 4d
and Supplementary Fig. 2). Notably, the stimulation of p38
phosphorylation by amlexanox was rapid, occurring over a time
course similar to its ability to relieve the feedback inhibition of
TBK1 phosphorylation8. The induction of Stat3 phosphorylation
in these adipocytes was not observed until after 4 h of treatment,
a lag consistent with the time course of secretion of IL-6 into the
media. Further supporting that Il6 induction by amlexanox is
mediated by a p38-dependent pathway downstream of cAMP,
pretreatment of adipocytes with the p38 inhibitor SB203,580
completely blocked the effect of amlexanox to increase both Il6
expression and IL-6 secretion (Fig. 4e,f). The dependency of
amlexanox-induced IL-6 secretion in adipocytes on p38 was
confirmed by short interfering RNA-mediated knockdown of p38
(Mapk14) prior to amlexanox treatment (Fig. 5 and Supplementary
Fig. 3). To verify that these effects of amlexanox were mediated by
its inhibition of IKK-e/TBK1, we utilized another structurally
unrelated inhibitor of these kinases CAY-10576. Treatment of
3T3-L1 adipocytes with CAY-10576 also increased the expression
and secretion of IL-6 in a p38-dependent manner (Supplementary
Fig. 4), confirming that this effect is due to inhibition of
IKK-e/TBK1, and not a non-specific effect of amlexanox.
Amlexanox-induced IL-6 signalling is p38-dependent in vivo.
We also explored the role of the cAMP/p38 pathway in vivo.
Similar to the induction of Il6 expression, amlexanox treatment
specifically increased cAMP levels in inguinal adipose tissue
(Fig. 6a). To demonstrate that the stimulatory effect of amlexanox
on IL-6 secretion was downstream of this pathway, we pretreated
mice by oral gavage with SB203,580. The stimulatory effect of
amlexanox on serum IL-6 levels was inhibited by p38 blockade
(Fig. 6b). Consistent with p38-dependent induction of IL-6 in
inguinal adipose tissue by amlexanox, we observed a significant
increase in Il6 mRNA levels as well as IL-6 precursor protein
levels, both of which were completely blocked by administration
of SB203,580 (Fig. 6c–e and Supplementary Fig. 5).
Hepatic Stat3 activation is observed with amlexanox treatment.
Next, we investigated whether the increase in serum IL-6 after
amlexanox treatment was associated with increased Stat3 activity
in the liver. Following administration of amlexanox to obese
mice, we assayed phosphorylation of Stat3 at tyrosine 705, which
mediates dimerization and subsequent nuclear localization and
transcriptional regulation. Hepatic Stat3 phosphorylation was
increased 4 h after amlexanox treatment, coincident with the
increase in serum IL-6 levels (Figs 7a,b and 1a, respectively,
Supplementary Fig. 6). As expected, Stat3 phosphorylation was
specifically associated with nuclear localization and DNA binding
in livers from the amlexanox-treated mice (Fig. 7c,d, respectively,
Supplementary Fig. 7). Furthermore, amlexanox treatment sig-
nificantly enriched Stat3 occupancy at the promoter of Socs3, a
well-known Stat3 target gene (Fig. 7e).
Activation of hepatic Stat3 is dependent on IL-6 signalling.
Pre-treatment with SB203,580 dose dependently decreased
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Figure 2 | Cellular specificity of amlexanox induced Il6 expression within fat. (a) Il6 expression in mature adipocytes, SVC and whole inguinal adipose
tissue (n¼ 8 mice fractionated individually per treatment). (b) Relative Emr1 (F4/80, a macrophage marker) and (c) Adipoq (a mature adipocyte marker)
expression in the different inguinal adipose tissue fractions (n¼8 mice per treatment). (d,e) Gating strategy for fluorescence-activated cell sorting
(FACS) of SVC. (f) Relative Emr1 and (g) Pdgfra (a preadipocyte marker) expression in different inguinal stromal cell fractions (n¼4 groups of 2).
(h) Il6 and (i) Tnfa expression in preadipocytes (CD45 , CD31 , Sca1þ ) and immune cells (CD45þ cells, both CD11cþ and CD11c populations)
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versus vehicle. Error bars presented as s.e.m.
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amlexanox-stimulated hepatic Stat3 phosphorylation, coordinat-
ing well with decreases in serum IL-6 levels (Figs 7f,g and 6b,
respectively, Supplementary Fig. 8). To causally link serum IL-6
to hepatic Stat3 phosphorylation, we utilized an IL-6 neutralizing
antibody. We tested a range of neutralizing antibody doses, all of
which efficiently blocked amlexanox-stimulated hepatic Stat3
phosphorylation (Fig. 7h and Supplementary Fig. 9). While the
IgG control antibody had no effect on the amlexanox or vehicle
control-treated mice, the IL-6 neutralizing antibody blocked the
stimulation of Stat3 phosphorylation in the amlexanox-treated
mice, but had no effect in the vehicle-treated mice (Fig. 7i,j and
Supplementary Fig. 10). We opted to use neutralizing antibodies
instead of genetic knockout of Il6 in these acute studies, thus
avoiding confounding effects of IL-6 deficiency throughout
development and on responses to diet.
Suppression of G6pc expression by Stat3. In the liver, Stat3
activity is associated with suppression of gluconeogenic gene
expression, specifically G6pc (refs 21–23). Increased binding of
Stat3 to the G6pc promoter at all four previously characterized
binding regions was observed in liver derived from amlexanox-
treated mice (Fig. 8a–d). Amlexanox treatment specifically
increased DNA binding by Stat3, but not FoxO1 or CREB,
indicating that the latter transcription factors are likely not
involved in the regulation of G6pc expression by the drug
(Fig. 8e). Consistent with the indirect effects of amlexanox in the
liver and lack of effect on CREB, amlexanox did not increase
cAMP levels in liver (Fig. 8f). We verified that treatment with
amlexanox results in reduced gluconeogenesis in obese mice after
only 3 days of treatment, by performing a pyruvate tolerance test
(Fig. 8g). Consistent with Stat3 activation by IL-6, the reduction
in hepatic glucose production was associated with reduced
expression of G6pc, and increased expression of Socs3 (Fig. 8h,i).
Furthermore, treatment with an IL-6 neutralizing antibody
completely blocked the anti-gluconeogenic effects of amlexanox
treatment, as determined by a pyruvate tolerance test (Fig. 9a,b).
The IL-6 neutralizing antibody also blocked the suppression of
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gluconeogenic gene expression by amlexanox, as well as the
induction of Socs3 expression (Fig. 9c,d).
Long-term benefits could be mediated by reduced inflammation.
The exact role of IL-6-mediated suppression of gluconeogenesis
in the long-term insulin-sensitizing effects of amlexanox remains
to be fully elucidated. IL-6 signalling has previously been shown
to have anti-inflammatory effects in liver as well as inflammatory
cells24,25. Therefore, it is possible that IL-6 stimulates the
resolution of chronic low-grade inflammation, as seen with
long-term amlexanox treatment13. Interestingly, serum IL-10
levels increase after both short and long-term amlexanox
treatment (Fig. 9e)13.
Potential relevance to human disease. To explore whether a
similar crosstalk occurs in humans, we investigated the relationship
between circulating IL-6 levels and measures of insulin sensitivity
in a small cohort of obese-diabetic patients treated with amlexanox
in a 12-week open-label clinical trial. In the mice, we observed the
most robust effects on IL-6 signalling over the first 24 h of drug
treatment. However, the earliest serum withdrawal in this clinical
trial was 1 week after initiation of treatment. In addition, differ-
ences in the dosage of amlexanox in this clinical trial further
obfuscate direct comparison with the IL-6 response in the animal
studies. Nevertheless, a relatively small but statistically significant
increase in serum IL-6 levels was observed after the sixth week of
treatment, in these patients (Fig. 10a). Increased serum IL-6 levels
were also observed during the first 2 weeks of treatment in four of
the six patients (Fig. 10b). The relative increase in serum IL-6 in
response to amlexanox treatment varied from patient to patient,
with some patients showing a more pronounced response than
others, even after baseline normalization (Fig. 10c).
Although fasting blood glucose levels and the homeostasis
model assessment-estimated insulin resistance (HOMA-IR)
score tended to be lower after amlexanox treatment, these
results did not reach statistical significance in this small cohort
(Supplementary Fig. 11). Hypothesizing that the insulin-
sensitizing effect of amlexanox treatment in humans is associated
with the relative IL-6 response, we performed a linear regression
analysis to determine whether the IL-6 response correlated with
improvements in the HOMA-IR score, as a measure of insulin
0
1
2
3
4
5
0 2 4 6 8 10
R
el
at
iv
e 
Il6
 
e
xp
re
ss
io
n
(a.
u.)
Time after treatment (h)
Vehicle
Amlexanox
0
50
100
150
200
250
300
0 6 12 18 24
IL
-6
 s
ec
re
tio
n
(pg
 pe
r w
ell
)
Time (h)
Vehicle
Amlexanox
*
*
*
Vehicle
Amlexanox
(25 mg kg–1)
RalA
p38
pTBK1
TBK1
Stat3
p-p38
Time (h) 1 4
pStat3
0
50
100
150
200
250
0 2 4 6 8 10
IL
-6
 s
ec
re
tio
n
(pg
 pe
r w
ell
)
Time (h)
Vehicle
Amlexanox
Vehicle, SB203,580
Amlexanox,
SB203,580
*
*
0
2
4
6
8
10
12
0 2 4 6 8
R
el
at
iv
e 
Il6
 
e
xp
re
ss
io
n
(a.
u.)
Time (h)
Vehicle
Amlexanox
*
*
*
*
Vehicle, SB203,580
Amlexanox,
SB203,580
4
1
2
1
4
3
4
1
2
1
4
3
# #
0
5
10
15
20
25
0 50 100 150
cA
M
P 
(pm
ol 
pe
r w
ell
)
Time (min)
Vehicle
Amlexanox
* *
*
*
98 kDa
98 kDa
98 kDa
98 kDa
36 kDa
50 kDa
50 kDa
*
a b
c d
e f
*
*
24862 1 4 24862
*# *# *# *
#
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sensitivity26–28. To quantify the IL-6 responsiveness for each
patient, we calculated the area under the curve for serum IL-6
levels after normalization to baseline for each patient. We
calculated the HOMA-IR score at the end of the 12-week study
as a per cent of baseline HOMA-IR for each individual
patient. There was a significant correlation (P value¼ 0.02, R2
value¼ 0.8) between the IL-6 response and improvements in the
HOMA-IR score (Fig. 10d). Although we have limited power in a
cohort of this size, these data are consistent with the
subcutaneous adipose tissue–liver communication axis that we
observed in mice treated with amlexanox. The complete results of
this clinical study will be reported elsewhere.
Discussion
The role of IL-6 in regulation of glucose homoeostasis has been
controversial29. IL-6 levels are chronically increased in obesity
and correlate with insulin resistance30–33, and reports suggest that
the cytokine might contribute to insulin resistance through
induction of Socs3 in hepatocytes34,35. However, other studies
have suggested a beneficial effect of the cytokine36–38. Differences
in the chronic versus acute metabolic effects of IL-6 may explain
why contradictory results have been observed in genetic mouse
models of disrupted IL-6 signalling. It is acutely secreted from
skeletal muscle in response to exercise, and studies have indicated
that it is produced from brown or white fat depots in response to
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sympathetic activation17,18,39–42. Adding further complexity
to the metabolic effects of IL-6, our results indicate that IL-6
may also represent a crucial player in a subcutaneous adipose
tissue–liver axis.
Taken together, these data indicate a new, previously
unappreciated crosstalk between subcutaneous adipose tissue
and liver in the control of glucose homoeostasis. These
findings suggest that activation of the inflammatory programme
in obesity induces expression of IKK-e/TBK1 in both
adipocytes and preadipocytes of subcutaneous fat, initiating a
process of catecholamine resistance that reduces energy
expenditure, but also suppresses the catecholamine-induced
increase in adipose IL-6 expression, thereby contributing
to elevated hepatic glucose production in obesity. Acute
inhibition of IKK-e/TBK1 by amlexanox reverses this catechola-
mine resistance, raising cAMP levels in subcutaneous
adipose tissue, and in the process dramatically increasing
IL-6 expression and subsequent activation of Stat3 in the
liver to suppress gluconeogenesis. These studies reinforce
the notion of IKK-e/TBK1 inhibition as a promising
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therapeutic strategy for the treatment of insulin resistance in
obese patients.
Methods
Reagents. All chemicals were obtained from Sigma-Aldrich unless otherwise
stated. TBK1 (3013), phosphorylated TBK1 (Ser172-5483) diluted 1:500, Stat3
(9139), phosphorylated Stat3 (Tyr705-9131), p38 (9212), phosphorylated p38
(Thr180/Tyr182-9211), tubulin (2128)-specific antibodies were purchased from
Cell Signaling. HDAC1 (H-51) and Stat3 (C-20)-specific antibodies were purchased
from Santa Cruz. RalA (610222)-specific antibody was obtained from BD
Bioscience and used at a dilution of 1:3,000. IL-6 antibody was obtained from
Abcam (ab6672). All antibodies were diluted 1:1,000 unless otherwise noted.
EDTA-free protease inhibitor tablet was purchased from Roche Diagnostics. For
in vitro experiments InSolution SB203,580 (1mgml 1) was purchased from
Calbiochem-EMD. For in vivo experiments SB203,580 powder was purchased from
Selleck Chemicals.
Animals. We fed wild-type male C57Bl/6 mice a high fat diet consisting of 45% of
calories from fat (D12451 Research Diets Inc.) starting at 8 weeks of age.
Amlexanox was administered by daily oral gavage at a dose of 25mg kg 1.
SB203,580 was administered by oral gavage at the indicated doses 30–60min prior
to amlexanox administration. Mice were preconditioned to the oral gavage for a
minimum of 1-week daily gavage with an equivalent volume of saline. Neutralizing
antibodies (R&D AB-406-NA and AB-108-C) were administered by intraperitoneal
injection just prior to oral gavage. During metabolic studies, such as pyruvate
tolerance tests, ear tag numbers were used to identify individual animals and the
researcher performing the test was blinded to the treatment group assignment
during data collection. Cohorts of 20–44 mice were produced in up to 20 in-house
breeding cages, and constructed to minimize the birthdate range. Mice were
assigned to treatment groups, such that prior to treatment the mean body weight,
as well as the s.d. of the body weight, was equal across treatment groups, using a
method similar to block randomization. Additional consideration was given to
housing, such that each cage contained multiple treatment groups, to avoid con-
founding by cage effects. Sample size was determined based on the available
cohorts and the number of treatment groups required. Mice were housed in a
specific pathogen-free facility with a 12-h light, 12-h dark cycle and given free
access to food and water, except when food was restricted during fasting. All
animal use was in compliance with the Institute of Laboratory Animal Research
Guide for the Care and Use of Laboratory Animals and approved by the University
Committee on Use and Care of Animals at the University of Michigan.
Pyruvate tolerance test. Fasting blood glucose levels from tail blood were mea-
sured after a 16-h fast, using the OneTouch Ultra glucometer (Lifescan). Mice were
then given an intraperitoneal injection of sodium pyruvate (P2256) at a dose of
1.5 g kg 1 body weight. Blood glucose levels were measured again at 15, 30, 45, 60,
90 and 120min post injection.
3T3-L1 differentiation. 3T3-L1 fibroblasts (American Type Culture Collection)
were cultured in DMEM containing 10% FBS. Once grown to confluence, adipo-
cyte differentiation was initiated using a three component cocktail containing
500 mM 3-Isobutyl-1-methylxanthine, 250 nM dexamethasone and 1 mgml 1
insulin for the first 3 days, followed by an additional 3 days of media containing
insulin and finally differentiation was completed in the culture media. Only cul-
tures in which 490% of cells displayed adipocyte morphology were used. Fully
differentiated adipocytes, which had been cultured in the FBS only media for
1 week, were serum starved for 3 h in media containing 0.5% FBS, then treated with
100 mM amlexanox or vehicle control. Where applicable, cells were pretreated for
30min with 5mM SB203,580 or vehicle control.
IL-6 measurement. Mouse IL-6 levels were quantified using Mouse IL-6 Quan-
tikine ELISA from R&D (SM6000B), with 50 ml of serum or cell culture media.
Human IL-6 serum levels were quantified using the Human IL-6 Quantikine ELISA
Kit (D6050) with 100ml serum.
cAMP measurement in cells and tissues. Tissue cAMP levels were determined
using the cAMP enzyme immunoassay kit (Sigma CA201) according to the
manufacturer’s instructions. Cellular cAMP levels were determined using the
cAMP enzyme immunoassay kit (Sigma CA200) according to the manufacturer’s
instructions.
Western blot analysis. We homogenized tissues in lysis buffer (50mM Tris
pH 7.5, 150mM NaCl, 2mM EDTA, 10% glycerol, 1% Triton X-100, 1mM
dithiothreitol, 1mM Na3VO4, 5mM NaF, 1mM phenylmethanesulfonylfluoride,
25mM glycerol 2-phosphate and freshly added protease inhibitor tablet) and
then incubated them for 1 h at 4 C. Cell lysates were produced in an SDS lysis
buffer (100mM Tris pH 7.5, 130mM NaCl, 1% NP-40, 0.1% SDS, 0.2%
sodium deoxycholate, 1mM Na3VO4, 1mM NaF, 100mM Na4P2O7, 1mM
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phenylmethanesulfonylfluoride, 25mM glycerol 2-phosphate and freshly added
protease inhibitor tablet) and sonicated for three 5 s pulses at an output power of 6.
We centrifuged crude lysates at 14,000 g for 15min twice and determined the
protein concentration using Bio-Rad Protein Assay Dye Reagent. Samples were
diluted in SDS sample buffer. Bound proteins were resolved by SDS–PAGE and
transferred to nitrocellulose membranes (Bio-Rad). Individual proteins were
detected with specific antibodies and visualized on film using horseradish
peroxidase-conjugated secondary antibodies (Bio-Rad) and Western Lightning
Enhanced Chemiluminescence (Perkin Elmer Life Sciences).
SVC isolation and fluorescence-activated cell sorting. The stromal vascular
fraction was separated from adipocytes by centrifugation after digestion. Excised
white adipose tissue was digested in RPMI with 0.5% BSA and 1mgml 1 type II
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collagenase for 30min at 37 C with gentle agitation. Then the cell suspension was
filtered through a 100 mm filter and centrifuged at 700 g for 5min to separate
floating adipocytes from SVC pellet, and RPMI with 0.5% BSA was used to wash
cells. The following antibodies were used for staining: anti-CD45(30-F11), anti-
CD31(390), anti-CD11c(N418) and anti-Sca-1(D7), all from eBioscience. Stained
SVC were sorted by flow cytometry on a MoFlo Astrios cell sorter (Beckman
Coulter) with the help of the University of Michigan’s Flow Cytometry Core.
Gene expression analysis. RNA extractions from tissues were performed using
the RNeasy Lipid Tissue Kit (Qiagen) While RNA extraction from cells utilized the
RNeasy Kit, we used the Superscript First-Strand Synthesis System for reverse
transcription–PCR (Invitrogen) with a 3:1 mixture of random hexamers/oligo dT
primers for reverse transcription. Real-time PCR amplification was performed
on samples in triplicate with Power SYBR Green PCR Master Mix (Applied
Biosystems) using the Applied Biosystems 7900HT Fast real-time PCR System and
quantified using an internal standard curve and Arbp as the control gene. The
sequences of all primers used in this study are listed in Supplementary Table 2.
RNA sequencing. Total RNA from mouse livers was isolated using Trizol
(Invitrogen) and the RNeasy mini kit according to the manufacturer’s instructions.
Biological triplicates of amlexanox-treated and non-treated tissues were used to
prepare sequencing libraries from 100–500 ng total RNA using the TruSeq RNA
Sample Preparation Kit v2 (Illumina) according to the manufacturer’s protocol.
Sample preparation. Briefly, mRNA was purified, fragmented and used for
first- and second-strand complementary DNA synthesis followed by adenylation
of 30 ends. Samples were ligated to unique adapters and subjected to PCR
amplification. Libraries were then validated using the 2100 BioAnalyzer (Agilent),
normalized and pooled for sequencing on the Illumina HiSeq 2000 using bar-coded
multiplexing and a 100 bp read length.
Data analysis. Read alignment and junction mapping was accomplished using
TopHat2 v2.0.4 using a 25 bp 50 segment seed for initial mapping followed by
differential gene expression analysis using Cuffdiff v2.0.2 to map reads to the
reference genome annotation, NCBI mouse build 37.2 (ref. 43). Median sequencing
read yield per replicate sample was 24.2M. Data were expressed as fragments per
kilobase of exon per million fragments mapped . Volcano plots were generated
from Cuffdiff output using CummeRbund v2.0.0 (ref. 43).
RNA-seq library construction. Single-cell complementary DNA size distribution
and concentration were assessed on a capillary electrophoresis-based fragment
analyser (Advanced Analytical). Illumina libraries were constructed in 96-well
plates using the Illumina Nextera XT DNA Sample Preparation kit as described
previously using the protocol supplied by Fluidigm. For each C1 experiment, a bulk
RNA control (about 200 cells) and a no-cell negative control were processed in
parallel in PCR tubes, using the same reagent mixes as used on chip. Libraries were
quantified by Bioanalyzer, using High Sensitivity DNA analysis kit, and also
fluorometrically using Qubit dsDNA HS Assay kits and a Qubit 2.0 Fluorometer
(Invitrogen, Life Technologies).
DNA sequencing. Single-cell Nextera XT (Illumina) libraries of one experiment
were pooled and 100 bp) paired-end were sequenced on Illumina HiSeq 2000 to a
depth of (2–6) 106 reads (three replicate experiments of distal mouse lung
epithelial cells at E18.5, one experiment at E14.5 and one experiment on adult AT2
cells) or 150 bp paired-end on Illumina MiSeq (one experiment at E16.5) to a depth
of 100,000–550,000 reads with v3 chemistry. CASAVA 1.8.2 was used to separate
out the data for each single cell by using unique barcode combinations from the
Nextera XT preparation and to generate *.fastq files.
KEGG pathway analysis. Normalized relative fold expression levels from
RNA-Seq were calculated for selected genes and differentially expressed genes
were determined. Pathway analysis was performed with DAVID Bioinformatics
Resources 6.7 (http://david.abcc.ncifcrf.gov/)44,45.
Chromatin immunoprecipitation. Flash-frozen vehicle or 8 h amlexanox-treated
liver samples (B400mg per chromatin immunoprecipitation (ChIP)) were thawed
on ice and homogenized in 10 volumes 2mM DSG (ProteoChem), incubated for
10min at room temperature and then passed through a 70 mM mesh to remove
extracellular debris. The homogenized cells were centrifuged, and pellets were
resuspended in 1% formaldehyde in PBS and incubated at room temperature for
10min. Formaldehyde crosslinking was quenched by the addition of glycine to a
final concentration of 125mM, and then incubated at room temperature for 5min.
The crosslinked cells were centrifuged and cell pellets were resuspended in ice cold
Cell Lysis Buffer to isolate nuclei. The nuclei were collected by centrifugation, and
then sonicated and chromatin was immunoprecipitated with 5 mg of Stat3 antibody
(C-20) or normal rabbit IgG (Cell Signaling, 2729) overnight. Immunoprecipitated
complexes were captured with protein A dynabeads (novex) for 90min at 4 C,
washed and eluted from beads. Complexes were then decrosslinked, DNA was
purified and real-time PCR was performed. Primer sequences used for ChIP can be
found in Supplementary Table 3.
Transcription factor DNA binding assays. Nuclear extracts from liver were
prepared using a nuclear extraction kit (Active Motif 40010). Ten nanograms of
nuclear extract were used to assay specific transcription factor DNA binding
activity using TransAM kits (Active Motif 45196, 46396 and 42092). These kits
utilize response element DNA affixed to the plate and specific primary antibodies
to quantify the relative DNA binding activity of specific transcription factors.
Clinical trial. Six obese type-2 diabetic patients (body mass index range 31 to
39 kgm 2, two males and four females, ages 24 to 68 years) were enroled in
clinical trial NCT01842282. After patients gave informed consent, they were
instructed to take amlexanox tablets (Takeda) in an open-label manner at a dosage
of 25mg three times daily. After 2 weeks, the dosage was increased to 50mg tablets
three times daily. Blood collection was performed at baseline and 1, 2, 4, 6 and 12
weeks of treatment, serum samples were frozen at  80 C for future combined
analysis. Patients were provided instructions for a standardized meal (600 kcal, 55%
carbohydrates, 30% fat and 15% protein) and then instructed to fast overnight after
2200 hours prior to the baseline and 12-week visits, such that HOMA-IR could be
calculated from measurements of fasted blood glucose and serum insulin. The
study was reviewed and approved by the University of Michigan Medical School
Institutional Review Board (IRBMED; HUM00065177).
Statistics. Averaged values are presented as the mean±s.e.m. Equality of variance
was determined using an f-test. Data were determined to be normally distributed as
the maximum and minimum values in each data set were o3 s.d. from the mean.
When comparing the two groups, statistical significance was determined using the
student’s t-test; except when the f-test indicated statistically different variances
(P valueo0.05), then a heteroscedastic t-test was used. When more than two
groups were investigated, we first performed an analysis of variance (ANOVA)
to establish that not all groups were equal. Following a statistically significant
ANOVA, we performed between group comparisons using the Tukey–Krammer
post-hoc analysis. Linear regression was used to determine correlation significance,
and displayed as the best fit line with a 95% confidence band. Linear regression,
ANOVA and Tukey–Krammer tests were performed using Prism version 6.0
(ref. 46).
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